35 results on '"Misinger I"'
Search Results
2. Hämokoagulationsfaktoren bei der Antikonzeption mit Antigest
3. [Recommendations for the diagnosis and therapy of vulvovaginitis].
4. [Do we know what "residua post partum" is?].
5. [Clinical study of steroid metabolism in the foetoplacental unit.--I. Levels of testosterone and 17beta-oestradiol in the umbilical blood in physiologic and pathologic pregnancies (author's transl)].
6. [About the clinical value of estimations of plasma progesterone levels and urinary pregnandiol output in cases of imminent abortion during the first half of pregnancy (author's transl)].
7. [Correlation of the diagnostic value of vaginal cytology and estimation of total urinary oestrogens in threatened pregnancies (author's transl)].
8. [Clinical significance of the determination of the plasma concentration of progesterone in threatened abortions during the first half of pregnancy].
9. [Humoral and nonspecific immunity at the end of pregnancy and in the puerperal period].
10. [A contribution to the problem concerning the bleeding in puerperium (author's transl)].
11. [Pharmacodynamic effects of dexamethasone and Partusisten on the levels of urinary estrogens and plasma estriol and progesterone in the 3d trimester of pregnancy].
12. [Treatment of purulent inflammations of the internal female genitalia].
13. [Correlation between the estimation of placental lactogen with other methods in risk pregnancies (author's transl)].
14. [Clinical monitoring for steroid metabolism of the fetoplacental unit.--II. Maternal blood testosterone and 17 B-estradiol levels in physiological and pathological pregnancies (author's transl)].
15. [Our experience with the glucose-6-phosphate and 6-phosphogluconate dehydrogenase tests in the diagnosis of gynecologic carcinoma].
16. [CONTRIBUTION TO THE TREATMENT OF ABSCESSING FORMS OF INFLAMMATION OF BARTHOLIN'S GLANDS].
17. [The health status of women in late gestosis (contribution to the study of hypertension)].
18. [Comments on the contraceptive efficiency of intrauterine devices].
19. [On the problem of work capacity of women treated for gynecological cancer].
20. [OUR EXPERIENCES WITH PERORAL CONTRACEPTION WITH PROGESTAGENS].
21. [Blood coagulation factors during contraception with Antigest].
22. [Indirect differential diagnosis of pituitary and ovarianinsufficiency].
23. [Excretion of 3-methoxy-4-hydroxymandelic acid (vanilmandelic acid), a principal catecholamine metabolite, in pregnancy and late gestoses].
24. [OUR EXPERIENCES WITH CONIZATION OF THE CERVIX UTERI].
25. [Two-phase hormonal contraception using Antigest B].
26. [Relation of vaginal biocenosis to inflammatory complications following interruption of pregnancy].
27. [Use of the preparation dl-13-ethyl-17-alpha-ethinyl-17-beta-hydroxy-4-gonen-3-on (WY 3707) in combination with ethinyl estradiol in gynecologic treatment and contraception].
28. Preventive gynecological surveys and detection of cancer of the cervix uteri at the 2d Gynecological and Obstetrical Clinic of the Charles University in Prague during the past 10 years
29. [Comparison of changes in activity of some hemocoagulation factors during contraception and therapy with combinations of synthetic steroids with varied gestagenic components].
30. [THE ASSISTANCE OF A CLINICAL LABORATORY IN SCREENING OF CERVICAL CARCINOMA].
31. [Contribution to the treatment of climateric and post-castration osteoporosis and osseous metastases of gynecological cancer].
32. [Hemocoagulation factors in contraception induced by Antigest].
33. [Use of laminaria for cervical dilatation in artificial interruption of pregnancy].
34. [Reasons for hospitalization of gynecological patients over 60 years of age].
35. [Survey of experience with Antigest].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.